MA5-15417

antibody from Invitrogen Antibodies

Targeting: PPARG NR1C3, PPARG1, PPARG2, PPARgamma

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15417

Provider

Invitrogen Antibodies

Product name

PPAR gamma Monoclonal Antibody (3A4A9, 1E6A1)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15417 targets PPARG in indirect ELISA, WB applications and shows reactivity with Human samples. The MA5-15417 immunogen is purified recombinant fragment of PPARG (aa170-270) expressed in E. Coli. .

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

3A4A9, 1E6A1

Vial size

100 µL

Concentration

Conc. Not Determined

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Characterization of a pluripotent stem cell-derived matrix with powerful osteoregenerative capabilities.

McNeill EP, Zeitouni S, Pan S, Haskell A, Cesarek M, Tahan D, Clough BH, Krause U, Dobson LK, Garcia M, Kung C, Zhao Q, Saunders WB, Liu F, Kaunas R, Gregory CA
Nature communications 2020 Jun 15;11(1):3025

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 Osteogenesis by ihMSCs is regulated by the cWnt/PPARgamma axis and PPARgamma inhibition increases osteogenesis and matrix productivity. a immunoblotting of ihMSC extracts (replicates of 3) for GSK3beta, beta-catenin, and PPARgamma isoforms in the presence and absence of osteogenic stimulus. ""Supernatant"" and ""Pellet"" represent cytosolic and insoluble extracts respectively. b Densitometry measurements of images in a . c GW9662 exposure under osteogenic conditions causes further upregulation of insoluble beta-catenin and downregulation of soluble GSK3beta. d Densitometry measurements of images in c . e GW9662 exposure under osteogenic conditions causes upregulation of the osteogenic biomarker ALP in ihMSCs. f Culture conditions as e , but mineralization assays with ARS. Representative ARS-stained monolayers are presented (left) with quantification of staining (right). bdl below detectable limits. g Osteogenically enhanced ihMSCs on monolayers generate higher yields of ECM by mass when treated with GW9662. h Protein content in ECM from OEihMSCs and bone marrow-derived OEhMSCs. i Calcium content in ECM recovered from OEihMSCs and BM-OEhMSCs. j GAG content in ECM recovered from OEihMSCs and BM-OEhMSCs treated with GW9662. Statistics: For panels b and d , data presented with means and SD and analyzed by two-tailed Student's t -test. For panels b , d , g - j , n = 3; for f , n = 5; for e , n = 4. Source data are provided as a Source Data file. For panels e - j , data pres